idiopathic pulmonary fibrosis

Air pollution exposure is associated with restrictive rather than obstructive ventilatory patterns
Kim de Jong, Judith Vonk, Wilma Zijlema, Ronald Stolk, Diana van der Plaat, Cleo van Diemen, Gerard Hoek, Bert Brunekreef, Dirkje Postma, Marike Boezen

European Respiratory Journal Sep 2016, 48 (suppl 60) PA398; DOI: 10.1183/13993003.congress-2016.PA398
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Bruno Crestani, Manuel Quaresma, Mitchell Kaye, Wibke Stansen, Susanne Stowasser, Michael Kreuter

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4960; DOI: 10.1183/13993003.congress-2016.OA4960
SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis
Argyris Tzouvelekis, Guoying Yu, Jose Herazo-Maya, Tony Woolard, Yi Zhang, Hojin Lee, Patty Lee, Erica Herzog, Anton Bennett, Naftali Kaminski

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4979; DOI: 10.1183/13993003.congress-2016.OA4979
Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres
Hannah Toellner, W. Beswick, M.G. Crooks, C. Donaldson, I. Forrest, S.P. Hart, C. Leonard, M. Major, A.J. Simpson, N. Chaudhuri

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4961; DOI: 10.1183/13993003.congress-2016.OA4961
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Ulrike Schmid, Benjamin Weber, Claudia Dallinger, Luca Richeldi, Christoph Hallmann, Ganesh Raghu, Matthias Freiwald

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4963; DOI: 10.1183/13993003.congress-2016.OA4963
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Elisabetta Balestro, Graziella Turato, Davide Biondini, Sofia Pavanello, Alessia Fraccaro, Chiara Rigobello, Erica Bazzan, Manuela Campisi, Simonetta Baraldo, Manuel Cosio, Marina Saetta, Paolo Spagnolo

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4965; DOI: 10.1183/13993003.congress-2016.OA4965
No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib
Toby Maher, Kevin R. Flaherty, Yoshikazu Inoue, Luca Richeldi, Moisés Selman, Wibke Stansen, Susanne Stowasser, Athol Wells

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4959; DOI: 10.1183/13993003.congress-2016.OA4959
Effect of baseline statin use on benefit of nintedanib
Michael Kreuter, Ulrich Costabel, Luca Richeldi, Vincent Cottin, Daniel Wachtlin, Susanne Stowasser, Martin Kolb

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4962; DOI: 10.1183/13993003.congress-2016.OA4962
LATE-BREAKING ABSTRACT: Significant improvement in refractory chronic cough with inhaled PA101 in patients with idiopathic pulmonary fibrosis: Results from phase 2 trial
Surinder Birring, Marlies Wijsenbeek, Sanjay Agrawal, Ahmet Tutuncu, Alyn Morice

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4958; DOI: 10.1183/13993003.congress-2016.OA4958
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Wim Wuyts, Benjamin Bondue, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Geert Verleden, Karl Richir, Christophe Compere, Natacha Gusbin, Guy Joos, Sofie Maddens

European Respiratory Journal Sep 2016, 48 (suppl 60) OA4572; DOI: 10.1183/13993003.congress-2016.OA4572

Main menu

User menu

Search

idiopathic pulmonary fibrosis

Pages